Tags : Pifeltro

Pharma

Merck’s Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) &

Shots: The approval is based on the results of P-III DRIVE-AHEAD and DRIVE-FORWARD trial assessing Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) & Pifeltro vs darunavir + ritonavir (DRV+r) + FTC/TDF or abacavir (ABC)/3TC respectively for a duration of 48/96 wks. DRIVE-AHEAD and DRIVE-FORWARD results: suppression of HIV-1 RNA @ 48 wks. (84%, 83% […]Read More

Regulatory

Merck’s Delstrigo and Pifeltro Receives CHMP Approval for the Treatment

Shots: • CHMP approval is based on two P-III trials i.e. DRIVE-AHEAD and DRIVE-FORWARD assessing (Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/TDF) and (Pifeltro vs darunavir +ritonavir +FTC/TDF/abacavir (ABC)/3TC)) for 48 wks., showing its safety and efficacy • On 30 Aug, 2018 the US FDA approved Delstrigo and Pifeltro for the treatment of HIV-1 infection in adult […]Read More